There's no reason whatsoever for this share price to rise to...

There's no reason whatsoever for this share price to rise to anywhere near 40c from any data currently available or likely to be available this year. There's not the slightest comparison with Idenix who had a stable of several compounds from classes with well-established efficacy in HCV. Biotron have no evidence whatsoever that BIT225 could have any place in modern HCV treatment protocols and won't have any such data for some time yet. And it is still not clear at all that there is a place for it in HIV treatment in the future. And where the money to fund the future trials is going to come from is still unknown. The recent price rise is not due to buying by 'people in the know' but due to a speculative upswing in biotech stocks in general - even the dog that is QRX has been going up.